FindTrial
Sign In

Intermittent repeated administration of levosimendan improves outcomes in patients undergoing cardiopulmonary bypass surgery

Intermittent repeated administration of levosimendan improves outcomes in patients undergoing cardiopulmonary bypass surgery

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046169
Enrollment
Unknown
Registered
2021-05-07
Start date
2021-05-16
Completion date
Unknown
Last updated
2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac disease

Interventions

Group L:IV Levosimendan 0-0.2 µg/kg/min for 24 h from the second day after admission
Group P:IV Placebo 0-0.2 µg/kg/min for 24 h from the second day after admission

Sponsors

Ethics Committee of Shandong First Medical University Affiliated Provincial Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged > 18 years; 2. Undergoing elective cardiac surgery.

Exclusion criteria

Exclusion criteria: 1. Suffering aortic stenosis; 2. Suffering hypertrophic obstructive cardiomyopathy; 3. Pregnant women; 4. Allergy to levosimendan; 5. Undergoing another drug trial.

Design outcomes

Primary

MeasureTime frame
Mortality;Low cardiac output syndrome;Acute renal failure;—

Countries

China

Contacts

Public ContactTan Qi

Shandong First Medical University Affiliated Provincial Hospital

deepblue1229@163.com+86 18753157303

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026